Henlius HANQUYOU - Trastuzumab
??? (trastuzumab, Zercepac in the EU) was successfully launched in China and Europe, becoming the first Chinese mAb biosimilar entering both the EU and China market. It is indicated for the treatment of HER2 positive early breast cancer, metastatic breast cancer and metastatic gastric cancer, which corresponds to all the approved indications of the trastuzumab originator. ??? is certificated by China and the EU GMP. It will bring more treatment options to patients with HER2 positive breast and gastric cancer worldwide.
-
Most popular related searches
Customer reviews
No reviews were found for Henlius HANQUYOU - Trastuzumab. Be the first to review!